Abstract: The present disclosure relates to a cell-derived vesicle rich in intracellular protein homeostasis regulators, and to a method of preparing same. The cell-derived vesicle of the present disclosure is characterized by containing an abundance of a specific protein compared to that in a naturally secreted exosome or the originated cell, and by virtue of said characteristic, can be utilized for various purposes such as in a pharmaceutical composition, a diagnostic composition, and a composition for drug delivery. Using the cell-derived vesicle rich in intracellular protein homeostasis regulators and the method of preparing same of the present disclosure, it is possible to easily deliver the intracellular protein homeostasis regulators to a target, such as a cell, thereby easily maintaining protein homeostasis in cells.

Abstract: The present invention relates to cell-derived vesicles with increased cellular uptake capacity and a method for producing same. The cell-derived vesicles of the present invention are produced by migrating cells to micropores, and exhibit the characteristic of expressing a protein marker that is different from that of exosomes naturally secreted by cells. The cell-derived vesicles with increased cellular uptake capacity, according to the present invention, have remarkably superior cellular uptake capacity as compared to natural exosomes secreted by cells, and thus can be effectively used to deliver various active substances, such as drugs and marker substances, into target cells.

Abstract: The present invention relates to a method for manufacturing cell-derived vesicles using a depth filter. The present invention has the effect of enabling cell-derived vesicles to be manufactured stably, economically, and in large quantities through a simplified process.

Abstract: Provided is a method for preparing cell-derived vesicles, and more particularly, a method for preparing cell-derived vesicles using a cell extruder, and a syringe-type cell extruder for effectively preparing cell-derived vesicles. According to the present invention, by using the method for preparing the cell-derived vesicles and the cell extruder, it is possible to prepare cell-derived vesicles in a stable, economical, and mass-producible manner.

Abstract: The present disclosure provides methods for processing cell-derived vesicles in which the cell-derived vesicles are not purified, prior to contacting with a fluorescent staining dye or an antibody. By utilizing a centrifugal filter, excess staining dye or antibody can be readily removed prior to analysis of one or more characteristics of the cell-derived vesicles. The methods provide rapid and simple processing and analysis, while maintaining a high concentration of cell-derived vesicles.

Abstract: The present invention relates to cell-derived vesicles comprising target protein Prokineticin receptor 1 (PROKR1), and a therapeutic agent for muscle diseases comprising the same. When applied to myoblasts, the cell-derived vesicles comprising PROKR1 according to the present invention promote muscle differentiation and induce differentiation into myotubes, and can thus be used to prevent or treat muscle diseases and can be widely used in the pharmaceutical industry and the field of health functional foods.

Abstract: A cell extruder of the present invention comprises: a pressure vessel in which a sample is dispensed; a regulator for adjusting a set pressure of nitrogen gas injected into the pressure vessel and then maintaining a constant pressure; an input valve for opening and closing the injection of nitrogen gas into the pressure vessel; an exhaust valve for removing the internal pressure of the pressure vessel; a filter holder which is provided with a membrane filter soaked with a reagent, so that the sample in the pressure vessel is fed through by the nitrogen gas and crushed into extracellular vesicles; and a collection container in which the extruded sample is stored. According to the present invention, pressure can be freely adjusted by the regulator. That is, the flow rate of the membrane according to pressure can be controlled, thus allowing the validation of a biopharmaceutical production method using an extracellular vesicle extruder.

Abstract: The present invention relates to a salivary gland therapeutic agent using the effects of a cell-derived vesicle of enhancing the proliferation capacity of salivary gland cells, promoting an amylase activity, and enhancing transepithelial resistance. A pharmaceutical composition comprising the cell-derived vesicle according to the present invention has the effects of enhancing the proliferation capacity of salivary gland cells damaged by radiation, promoting amylase activity, increasing transepithelial resistance, enhancing the expression of Aquaporin 5, and increasing the amount of saliva secretion. Therefore, the pharmaceutical composition comprising the cell-derived vesicle of the present invention can be used for preventing and treating salivary gland diseases, and thus can be widely used in the pharmaceutical industry and health functional food field.

Abstract: Provided herein is a method for treating a pulmonary disease using mesenchymal stem cell-derived artificial nanosomes exhibiting a significantly excellent capability to regenerate alveoli compared to mesenchymal stem cells themselves and natural exosomes derived from human adipose-derived mesenchymal stem cells, wherein the mesenchymal stem cell-derived artificial nanosomes of the present disclosure may be collected through a simple production method using an extruder and an ultracentrifuge, instead of treating mesenchymal stem cells with a separate chemical substance and the potential side effects caused by stem cell therapeutic agents is low.